Belay Diagnostics Reports 82% Clinical Impact Rate for Summit™ and Vantage™ in CNS Lymphoma Study

Belay Diagnostics announced the publication of a new retrospective study demonstrating that its Summit and Vantage tests ...
Seeking Alpha

Belay Diagnostics Announces US Commercial Launch of Summit™: Breakthrough CSF Testing for CNS Cancer Detection and Management

Validation Data on More Than 100 Patients published in Journal of Molecular Diagnostics CHICAGO, April 25, 2025 /PRNewswire/ -- Belay Diagnostics, a CLIA/CAP accredited laboratory focused on the ...
Seeking Alpha

Plus Therapeutics Provides Business Update on CNSide Diagnostics Subsidiary

HOUSTON, June 26, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (PSTV) (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced ...
Milwaukee Journal Sentinel

The End Brain Cancer Initiative Partners with Belay Diagnostics to Raise Awareness of Diagnostic Testing for CNS Tumors

REDMOND, WA, UNITED STATES, January 15, 2026 /EINPresswire.com/ — The End Brain Cancer Initiative Partners with Belay Diagnostics to Raise Awareness of Diagnostic ...